Genetic basis for personalized medicine in asthma

Portelli, Michael A.; Sayers, Ian

Abstract

There is heterogeneity in patient responses to current asthma medications. Significant progress has been made identifying genetic polymorphisms that influence the efficacy and potential for adverse effects to asthma drugs, including; β2-adrenergic receptor agonists, corticosteroids and leukotriene modifiers. Pharmacogenetics holds great promise to maximise clinical outcomes and minimize adverse effects. Asthma is heterogeneous with respect to clinical presentation and inflammatory mechanisms underlying the disease, which is likely to contribute to variable results in clinical trials targeting specific inflammatory mediators. Genome-wide association studies have begun to identify genes underlying asthma (e.g., IL1RL1), which represent future therapeutic targets. In this article, we review and update the pharmacogenetics of current asthma therapies and discuss the genetics underlying selected Phase II and future targets.

Citation

Portelli, M. A., & Sayers, I. (2012). Genetic basis for personalized medicine in asthma. Expert Review of Respiratory Medicine, 6(2), https://doi.org/10.1586/ers.12.9

• Journal Article Type: Article
• Publication Date: Apr 1, 2012
• Deposit Date: Mar 27, 2014
• Publicly Available Date: Mar 27, 2014
• Journal: Expert Review of Respiratory Medicine
• Print ISSN: 1747-6348
• Electronic ISSN: 1747-6356
• Publisher: Taylor and Francis
• Peer Reviewed: Peer Reviewed
• Volume: 6
• Issue: 2
• DOI: https://doi.org/10.1586/ers.12.9
• Public URL: https://nottingham-repository.worktribe.com/output/1007694
• Publisher URL: http://www.expert-reviews.com/doi/abs/10.1586/ers.12.9